Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prandilin vs NovoRapid in Newly Diagnosed T2DM
NCT03226210Phase 4Completed
- Sponsor
- Nanjing First Hospital
- Start
- Feb 2015
- Primary completion
- May 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Mean Amplitude of Glycemic Excursions at 14 days. Started Feb 2015; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03226210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226210.